EUVIMEDEUVIMED entdecken
Open Access

Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients

Guohua An iD, C Buddy Creech, Nan Wu iD, Roger L Nation iD, Kenan Gu, Demet Nalbant, Natalia Jimenez-Truque, William Fissell, Pratish C Patel, Nicholas Fishbane, Amy Watanabe, Stephanie Rolsma iD und 3 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Guohua An und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Critical Illness. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to identify rational empirical dosing strategies for cefepime treatment in critically ill patients by utilizing population pharmacokinetics and target attainment analysis. Patients and methods A prospective and opportunistic pharmacokinetic (PK) study was conducted in 130 critically ill patients in two ICU sites. The plasma concentrations of cefepime were determined using a validated LC-MS/MS method. All cefepime PK data were analysed simultaneously using the non-linear mixed-effects modelling approach. Monte Carlo simulations were performed to evaluate the PTA of cefepime at different MIC values following different dose regimens in subjects with different renal functions.

Results

The PK of cefepime in critically ill patients was best characterized by a two-compartment model with zero-order input and first-order elimination. Creatinine clearance and body weight were identified to be significant covariates. Our simulation results showed that prolonged 3 h infusion does not provide significant improvement on target attainment compared with the traditional intermittent 0.5 h infusion. In contrast, for a given daily dose continuous infusion provided much higher breakpoint coverage than either 0.5 h or 3 h intermittent infusions. To balance the target attainment and potential neurotoxicity, cefepime 3 g/day continuous infusion appears to be a better dosing regimen than 6 g/day continuous infusion.

Conclusions

Continuous infusion may represent a promising strategy for cefepime treatment in critically ill patients. With the availability of institution- and/or unit-specific cefepime susceptibility patterns as well as individual patients’ renal function, our PTA results may represent useful references for physicians to make dosing decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCritical IllnessHumansCefepimeChromatography, LiquidProspective StudiesTandem Mass SpectrometryMonte Carlo MethodMicrobial Sensitivity Tests

Substanzen

CefepimeAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
  • Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
  • Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA.

ORCID-Profile: Guohua An, Nan Wu, Roger L Nation, Stephanie Rolsma, Cornelia B Landersdorfer

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institutes of Allergy and Infectious Diseases
  • National Institutes of Health
  • Vaccine and Treatment Evaluation Unit

Zitieren

APA

An, G., Creech, C. B., Wu, N., Nation, R. L., Gu, K., Nalbant, D., Jimenez-Truque, N., Fissell, W., Patel, P. C., Fishbane, N., Watanabe, A., Rolsma, S., Kirkpatrick, C. M. J., Landersdorfer, C. B., & Winokur, P. (2023). Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad106

Vancouver

An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, et al. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad106

BibTeX
@article{An2023,
  author = {An, Guohua and Creech, C Buddy and Wu, Nan and Nation, Roger L and Gu, Kenan and Nalbant, Demet and Jimenez-Truque, Natalia and Fissell, William and Patel, Pratish C and Fishbane, Nicholas and Watanabe, Amy and Rolsma, Stephanie and Kirkpatrick, Carl M J and Landersdorfer, Cornelia B and Winokur, Patricia},
  title = {Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad106}
}
Kostenlos starten →